Literature DB >> 28712967

Clinical utility of the Calgary Depression Scale for Schizophrenia in individuals at ultra-high risk of psychosis.

Gurpreet Rekhi1, Wai Yee Ng2, Jimmy Lee3.   

Abstract

There is a pressing need for reliable and valid rating scales to assess and measure depression in individuals at ultra-high risk (UHR) of psychosis. The aim of this study was to examine the clinical utility of the Calgary Depression Scale for Schizophrenia (CDSS) in individuals at UHR of psychosis. 167 individuals at UHR of psychosis were included as participants in this study. The Structured Clinical Interview for DSM-IV Axis I Disorders, CDSS, Beck Anxiety Inventory and Global Assessment of Functioning were administered. A receiver operating characteristic (ROC) curve analysis and factor analyses were performed. Cronbach's alpha was computed. Correlations between CDSS factor scores and other clinical variables were examined. The median CDSS total score was 5.0 (IQR 1.0-9.0). The area under ROC curve was 0.886 and Cronbach's alpha was 0.855. A score of 7 on the CDSS yielded the highest sensitivity and specificity in detecting depression in UHR individuals. Exploratory factor analysis of the CDSS yielded two factors: depression-hopelessness and self depreciation-guilt, which was confirmed by confirmatory factor analysis. Further analysis showed that the depression-hopelessness factor predicted functioning; whereas the self depreciation-guilt factor was related to the severity of the attenuated psychotic symptoms. In conclusion, the CDSS demonstrates good psychometric properties when used to evaluate depression in individuals at UHR of psychosis. Our study results also support a two-factor structure of the CDSS in UHR individuals.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Calgary Depression Scale for Schizophrenia; Depression; Psychometric properties; Ultra-high risk

Mesh:

Year:  2017        PMID: 28712967     DOI: 10.1016/j.schres.2017.06.056

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  2 in total

1.  Persistent negative symptoms in youth at clinical high risk for psychosis: A longitudinal study.

Authors:  D J Devoe; L Lu; T D Cannon; K S Cadenhead; B A Cornblatt; T H McGlashan; D O Perkins; L J Seidman; M T Tsuang; S W Woods; E F Walker; D H Mathalon; C E Bearden; J Addington
Journal:  Schizophr Res       Date:  2020-04-30       Impact factor: 4.939

2.  The latent structure of depressive symptoms across clinical high risk and chronic phases of psychotic illness.

Authors:  Teresa Vargas; Anthony O Ahmed; Gregory P Strauss; Cassandra M Brandes; Elaine F Walker; Robert W Buchanan; James M Gold; Vijay A Mittal
Journal:  Transl Psychiatry       Date:  2019-09-16       Impact factor: 6.222

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.